Two 59%+ winners, four above 25% in Aug – How this AI model keeps picking winners
In a challenging market environment, Myriad Genetics , Inc. (NASDAQ:MYGN) stock has touched a 52-week low, reaching $8.37 USD. According to InvestingPro analysis, the company’s RSI indicates oversold conditions, while the stock appears undervalued based on Fair Value calculations. This significant downturn reflects a broader trend for the genetic testing and precision medicine company, which has seen its stock price plummet by -56.65% over the past year. Despite challenges, the company has achieved 11.21% revenue growth in the last twelve months. Investors have been closely monitoring Myriad Genetics as the company grapples with industry-wide pressures and internal challenges that have weighed heavily on its financial performance and market valuation. The 52-week low serves as a critical indicator of the current investor sentiment and the hurdles that Myriad Genetics faces in its efforts to stabilize and grow its market position. For deeper insights, InvestingPro subscribers can access 10+ additional ProTips and a comprehensive analysis report on MYGN’s outlook.
In other recent news, Myriad Genetics reported fourth-quarter revenues of $211 million, aligning with its preannouncement range but falling short of the Street’s expectation of $213 million. The company achieved adjusted gross margins of 72.0% and adjusted EBITDA of $11 million, surpassing expectations. However, its 2025 revenue guidance of $840-860 million is below prior forecasts. Analyst firms have responded with several adjustments to their ratings and price targets. Scotiabank (TSX:BNS) reduced its price target to $20 while maintaining a Sector Outperform rating, citing potential growth in Oncology and Women’s Health. Piper Sandler upgraded the stock to Overweight with a new target of $12.50, highlighting the opportunity for a strategic reset under new CEO Sam Raha. Morgan Stanley (NYSE:MS) lowered its target to $16, maintaining an Equalweight rating, and noted near-term uncertainties. JPMorgan and Jefferies also cut their targets to $12 and $11, respectively, both expressing caution due to ongoing challenges and the CEO transition. These developments reflect a period of transition and strategic reassessment for Myriad Genetics.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.